



FORM PTO - 1449

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RD	A67	6,617,135	9/9/03	Gillies <i>et al.</i>			
	A68	6,485,726 B1	11/26/02	Blumberg <i>et al.</i>			
	A69	6,475,717 B1	11/5/02	Enssle <i>et al.</i>			
	A70	6,335,176 B1	1/1/02	Inglese <i>et al.</i>			
	A71	2003/0166877 A1	9/4/03	Gillies <i>et al.</i>			
	A72	2003/0166163 A1	9/4/03	Gillies			
	A73	2003/0157054 A1	8/21/03	Gillies <i>et al.</i>			
	A74	2003/0105294 A1	6/5/03	Gillies <i>et al.</i>			
	A75	2003/0049227 A1	3/13/03	Gillies <i>et al.</i>			
	A76	2003/0044423 A1	3/6/03	Gillies <i>et al.</i>			
	A77	2002/0193570 A1	12/19/02	Gillies <i>et al.</i>			
	A78	2002/0192222 A1	12/19/02	Blumberg <i>et al.</i>			
	A79	2002/0147311 A1	10/10/02	Gillies <i>et al.</i>			
RD	A80	2002/0081664 A1	6/27/02	Lo <i>et al.</i>			
	A81	2001/0053539 A1	12/20/01	Lauffer <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
RD	B96	1 088 888 A1	4/4/01	EP					Y
	B97	WO 03/077834 A2	9/2/03	PCT					Y
	B98	WO 03/048334 A2	6/12/03	PCT					Y
	B99	WO 02/090566 A2	11/14/02	PCT					Y
	B100	WO 02/079415 A2	10/10/02	PCT					Y
	B101	WO 02/079232 A2	10/10/02	PCT					Y
	B102	WO 02/072605 A2	9/19/02	PCT					Y
RD	B103	WO 02/066514 A2	8/29/02	PCT					Y

EXAMINER

DATE CONSIDERED

12/19/03

FORM PTO - 1449				ATTORNEY DOCKET NO.: MERCK-2056					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANTS: Hartmann <i>et al.</i>					
				SERIAL NO.: 09/708,506			CONF. NO.: 2626		
				FILING DATE: November 9, 2000 GROUP: 1647					
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>RM</i>	B104	WO 02/02143 A2	1/10/02	PCT					Y
	B105	WO 01/58957 A2	8/16/01	PCT					Y
<i>RM</i>	B106	WO 01/36489 A2	5/25/01	PCT					Y
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
<i>RM</i>	C182	Angal et al. (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30:105-108.							
	C183	Bitoni et al. (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.							
	C184	Darling et al. (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.							
	C185	Fibi et al. (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85:1229-1236.							
	C186	Hammerling et al. (1996), "In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469.							
	C187	Kitamura et al. (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.							
	C188	Locatelli et al. (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.							
	C189	Spiekermann et al. (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.							
<i>RM</i>	C190	Syed et al. (1998), "Efficiency of signalling through cytokine receptors depends critically on receptor orientation," <u>Nature</u> , 395:511-516.							
EXAMINER <i>R M Keefy</i>				DATE CONSIDERED <i>12/19/03</i>					

FORM PTO - 1449
INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>RA</i>	A1	07/348,237	5/5/89	Rosenblum <i>et al.</i>			
	A2	4,196,265	4/1/80	Koprowski <i>et al.</i>			
	A3	4,469,797	9/4/84	Albarella			
	A4	4,676,980	6/30/87	Segal <i>et al.</i>			
	A5	4,816,567	3/28/89	Cabilly <i>et al.</i>			
	A6	4,946,778	8/7/90	Ladner <i>et al.</i>			
	A7	5,019,368	5/28/91	Epstein <i>et al.</i>			
	A8	5,073,627	12/17/91	Curtis <i>et al.</i>			
	A9	5,114,711	5/19/92	Bell <i>et al.</i>			
	A10	5,116,964	5/26/92	Capon <i>et al.</i>			
	A11	5,199,942	4/6/93	Gillis			
	A12	5,225,538	7/6/93	Capon <i>et al.</i>			
	A13	5,225,539	7/6/93	Winter			
	A14	5,258,498	11/2/93	Huston <i>et al.</i>			
	A15	5,314,995	5/24/94	Fell, Jr. <i>et al.</i>			
	A16	5,349,053	9/20/94	Landolfi			
	A17	5,359,035	10/25/94	Habermann			
	A18	5,514,582	5/7/96	Capon <i>et al.</i>			
	A19	5,538,866	7/23/96	Israeli <i>et al.</i>			
	A20	5,541,087	7/30/96	Lo <i>et al.</i>			
	A21	5,543,297	8/6/96	Cromlish, <i>et al.</i>			
	A22	5,552,524	09/03/96	Basinski <i>et al.</i>			
<i>RA</i>	A23	5,585,089	12/17/96	Queen <i>et al.</i>			
EXAMINER	<i>R M 10/19/03</i>			DATE CONSIDERED	<i>12/19/03</i>		



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RD	A24	5,609,846	3/11/97	Goldenberg			
	A25	5,624,821	4/29/97	Winter <i>et al.</i>			
	A26	5,639,725	6/17/97	O'Reilly <i>et al.</i>			
	A27	5,645,835	7/8/97	Fell, Jr. <i>et al.</i>			
	A28	5,650,150	7/22/97	Gillies			
	A29	5,650,492	7/22/97	Gately <i>et al.</i>			
	A30	5,667,776	9/16/97	Zimmerman <i>et al.</i>			
	A31	5,679,543	10/21/97	Lawlis			
	A32	5,691,309	11/25/97	Basinski <i>et al.</i>			
	A33	5,709,859	1/20/98	Aruffo <i>et al.</i>			
	A34	5,719,266	02/17/98	DiMarchi <i>et al.</i>			
	A35	5,723,125	3/3/98	Chang <i>et al.</i>			
	A36	5,726,044	3/10/98	Lo <i>et al.</i>			
	A37	5,728,552	3/17/98	Fujisawa <i>et al.</i>			
	A38	5,733,876	3/31/98	O'Reilly <i>et al.</i>			
	A39	5,756,461	05/26/98	Stephens			
	A40	5,759,551	6/2/98	Ladd <i>et al.</i>			
	A41	5,770,195	6/23/98	Hudziak <i>et al.</i>			
	A42	5,800,810	9/1/98	Doyle <i>et al.</i>			
	A43	5,807,715	9/15/98	Morrison <i>et al.</i>			
	A44	5,827,516	10/27/98	Urban <i>et al.</i>			
	A45	5,837,682	11/17/98	Folkman <i>et al.</i>			
	A46	5,843,423	12/1/98	Lyman <i>et al.</i>			
	A47	5,854,205	12/29/98	O'Reilly <i>et al.</i>			
	A48	5,858,347	1/12/99	Baur <i>et al.</i>			
RB	A49	5,885,795	3/23/99	O'Reilly <i>et al.</i>			
EXAMINER <i>R.M. OUBZy</i>				DATE CONSIDERED <i>12/19/03</i>			



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RP	A50	5,886,178	3/23/99	Allen et al.			
	A51	5,888,772	3/30/99	Okasinski et al.			
	A52	5,908,626	6/1/99	Chang et al.			
	A53	5,922,685	7/13/99	Rakhmievich et al.			
	A54	5,994,126	11/30/99	Steinman et al.			
	A55	6,080,409	6/27/00	Laus et al.			
	A56	6,086,875	7/11/00	Blumberg et al.			
	A57	6,100,387	8/8/00	Herrmann et al.			
	A58	6,169,070 B1	1/2/01	Chen et al.			
	A59	6,171,588 B1	1/9/01	Carron et al.			
	A60	6,277,375 B1	8/21/01	Ward			
	A61	6,348,192 B1	2/19/02	Chan et al.			
	A62	6,406,689 B1	6/18/02	Falkenberg et al.			
	A63	6,444,792 B1	9/3/02	Gray et al.			
	A64	5,856,298	1/5/99	Strickland			
	A65	5,688,679	11/18/97	Powell			
RP	A66	5,441,868	8/15/95	Lin			

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNT RY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
RP	B1	0 158 198 A1	10/16/85	EP					Y
	B2	0 211 769 A2	2/25/87	EP					Y
	B3	0 256 714 A2	2/24/88	EP					Y
	B4	0 294 703 A2	12/14/88	EP					Y
	B5	0 308 936 B1	3/29/89	EP					Y
RP	B6	0 314 317 B1	5/3/89	EP					Y

EXAMINER

DATE CONSIDERED

12/19/03

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNT RY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
<i>ms</i>	B7	0 318 554 B1	6/7/89	EP					Y
	B8	0 319 012 A2	6/7/89	EP					Y
	B9	0 326 120 B1	8/2/89	EP					Y
	B10	0 350 230 A2	1/10/90	EP					Y
	B11	0 375 562 B1	6/27/90	EP					Y
	B12	0 396 387 A2	11/7/90	EP					Y
	B13	0 439 095 A2	7/31/91	EP					Y
	B14	0 511 747 A1	11/4/92	EP					Y
	B15	0 601 043 B1	6/15/94	EP					Y
	B16	0 706 799 A2	4/17/96	EP					Y
	B17	0 790 309 A1	8/20/97	EP					Y
	B18	21725/88	3/23/89	AU					Y
	B19	93100115.3	7/14/93	CN					N
	B20	93100115.3	7/14/93	CN				Y	Y
	B21	37 12985 A1	11/3/88	DE					N
	B22	37 12985	11/2/88	DE				Y	Y
	B23	2 292 382 A	2/21/96	GB					Y
	B24	63-267278	11/4/88	JP					N
	B25	63-267278	11/4/88	JP				Y	Y
	B26	63-267296	11/4/88	JP					N
	B27	63-267296	11/4/88	JP				Y	Y
	B28	0 237 019 A2	9/16/87	EP				English counterpart of 63-267296 (B26)	Y
	B29	WO 86/01533	3/13/86	PCT					Y
<i>ms</i>	B30	WO 88/00052	1/14/88	PCT					Y
EXAMINER <i>Km Koerby</i>					DATE CONSIDERED <i>12/19/02</i>				

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
B31		WO 88/09344	12/1/88	PCT					Y
B32		WO 89/02922	4/6/89	PCT					Y
B33		WO 89/09620	10/19/89	PCT				Abstract in English	N
B34		WO 90/03801	4/19/90	PCT					Y
B35		WO 91/00360	1/10/91	PCT					Y
B36		WO 91/04329	04/04/91	PCT					Y
B37		WO 91/08298	6/13/91	PCT					Y
B38		WO 91/13166	9/5/91	PCT					Y
B39		WO 91/14438	10/3/91	PCT					Y
B40		WO 92/02240	2/20/92	PCT					Y
B41		WO 92/08495	5/29/92	PCT					Y
B42		WO 92/08801	5/29/92	PCT					Y
B43		WO 92/16562	10/1/92	PCT					Y
B44		WO 93/03157	2/18/93	PCT					Y
B45		WO 93/10229	5/27/93	PCT					Y
B46		WO 95/05468	2/23/95	PCT					Y
B47		WO 95/21258	8/10/95	PCT					Y
B48		WO 95/28427	10/26/95	PCT					Y
B49		WO 95/31483	11/23/95	PCT					Y
B50		WO 96/04388	02/15/96	PCT					Y
B51		WO 96/05309	2/22/96	PCT					Y
B52		WO 96/08570	3/21/96	PCT					Y
B53		WO 96/18412	6/20/96	PCT					Y
B54		WO 96/31526	10/10/96	PCT					Y

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
hs	B55	WO 97/00317	1/3/97	PCT					Y
	B56	WO 97/00319	1/3/97	PCT					Y
	B57	WO 97/15666	5/1/97	PCT					Y
	B58	WO 97/20062	6/5/97	PCT					Y
	B59	WO 97/24137	7/10/97	PCT					Y
	B60	WO 97/24440	7/10/97	PCT					Y
	B61	WO 97/26335	7/24/97	PCT					Y
	B62	WO 97/30089	8/21/97	PCT					Y
	B63	WO 97/33617	9/18/97	PCT					Y
	B64	WO 97/33619	9/18/97	PCT					Y
	B65	WO 97/34631	9/25/97	PCT					Y
	B66	WO 97/43316	11/20/97	PCT					Y
	B67	WO 98/00127	1/8/98	PCT					Y
	B68	WO 98/06752	2/19/98	PCT					Y
	B69	WO 98/28427	7/2/98	PCT					Y
	B70	WO 98/30706	7/16/98	PCT					Y
	B71	WO 98/46257	10/22/98	PCT					Y
	B72	WO 98/59244	12/30/98	PCT					Y
	B73	WO 99/02709	01/21/99	PCT					Y
	B74	WO 99/03887	01/28/99	PCT					Y
	B75	WO 99/29732	6/17/99	PCT					Y
	B76	WO 99/43713	9/2/99	PCT					Y
	B77	WO 99/52562	10/21/99	PCT					Y
hs	B78	WO 99/53958	10/28/99	PCT					Y
EXAMINER <i>R M Kelly</i>					DATE CONSIDERED <i>12/19/03</i>				



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
AK	B79	WO 99/60128	11/25/99	PCT					Y
	B80	WO 99/62944	12/09/99	PCT					Y
	B81	WO 00/11033	3/2/00	PCT					Y
	B82	WO 00/34317	06/15/00	PCT					Y
	B83	WO 00/40615	7/13/00	PCT					Y
	B84	WO 00/69913	11/23/00	PCT					Y
	B85	WO 00/78334 A1	12/28/00	PCT					Y
	B86	WO 01/07081 A1	2/1/01	PCT					Y
	B87	WO 01/10912 A1	2/15/01	PCT					Y
	B88	WO 03/015697 A2	2/27/03	PCT					Y
	B89	0 640 619 A1	3/1/95	EP					Y
	B90	0 668 353 A1	8/23/95	EP					Y
	B91	WO 94/24160	10/27/94	PCT					Y
	B92	WO 94/25055	11/10/94	PCT					Y
	B93	WO 99/66054	12/23/99	PCT					Y
	B94	WO 00/68376	11/16/00	PCT					Y
AK	B95	WO 00/24893	5/4/00	PCT					Y

EXAM.
INIT.

OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)

AK	C1	Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization," <u>Journal of Protein Chemistry</u> , 11:5:433-444.
	C2	Abstract XP-002116766, (1996), "Prostaglandins, their inhibitors and cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54:2:83-94.
AK	C3	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.

EXAMINER

DATE CONSIDERED

12/19/03


FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann <i>et al.</i> SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
h	C4	Arenberg et al. (1996), "Interferon- γ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992.	
	C5	Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Experimental Medicine</u> , 167:612-622	
	C6	Bachelot et al., (March 1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856.	
	C7	Barnett et al., (1994), "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.	
	C8	Baselga, et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin TM) Enhances the Antitumor activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831.	
	C9	Batova et al., (1999), "The Ch 14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263.	
	C10	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Mol. Immunol.</u> , 30:379-386.	
	C11	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci.</u> , 93:7826-7831.	
	C12	Becker et al., (1996), "Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707.	
	C13	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Ann. Rev. Biochem.</u> , 57:505-518.	
	C14	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher, ed., 175-193.	
	C15	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221.	
	C16	Boehm et al., (1997), "Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance," <u>Nature</u> , 390:404-407.	
h	C17	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194.	
EXAMINER		DATE CONSIDERED	



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C18	Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164.	
	C19	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307:2:411-415.	
	C20	Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138.	
	C21	Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>Journal of Experimental Medicine</u> , 173:6:1483-1491.	
	C22	Cao et al., (1996), "Kringle Domains of Human Angiostatin," <u>The Journal of Biological Chemistry</u> , 271:46:29461-29467.	
	C23	Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272:36:22924-22928.	
	C24	Capon et al., (1989), "Designing CD4 immunoadhesins for AIDS therapy," <u>Nature</u> , 337:525-531.	
	C25	Caton et al., (1986), "Structural and functional implications of a restricted antibody response to a defined antigenic region on the influenza virus hemagglutinin," <u>The EMBO Journal</u> , 5:7:1577-1587.	
	C26	Chan et al., (1991), "Induction of Interferon γ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , pp. 869-879.	
	C27	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390.	
	C28	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271:23:13349-13355.	
	C29	Chaudhary et al., (1988), "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," <u>Nature</u> , 335:370-372.	
	C30	Chaudhary et al., (1989), "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <u>Nature</u> , 339:394-397.	
	C31	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159:1:351-358.	
	C32	Cheon et al., (1994), "High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993.	
EXAMINER		DATE CONSIDERED 12/19/00	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann <i>et al.</i> SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C33	Chuang et al., (1993), "Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes," <u>Gynecol. Oncol.</u> , 49:291-298.	
	C34	Cohen, S. L. et al., (1996), "Human leptin characterization," <u>Nature</u> , 382:589.	
	C35	Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621.	
	C36	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 that Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci.</u> , 85:7709-7713.	
	C37	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534.	
	C38	D'Amato et al., (1994), "Thalidomide is an inhibitor of angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085.	
	C39	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398.	
	C40	Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proceedings of the National Academy of Sciences of USA</u> , 95:10443-10448.	
	C41	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem. Supp.</u> , 161:156-166.	
	C42	Eisenthal, (1990), "Indomethacin up-regulated the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <u>Cancer Immunol. Immunotherap.</u> 31:342-348.	
	C43	Fell et al., (1991), "Genetic Construction and Characterization of Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>The J. of Immunology</u> , 146:7:2446-2452.	
	C44	Fell et al., (1992), "Chimeric L6 antitumor antibody," <u>The J. of Biol. Chem.</u> , 267:15552-15558.	
	C45	Friedman, J. M. et al., (1998), "Leptin and the regulation of body weight in mammals," <u>Nature</u> , 395:763-770.	
	C46	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342.	
	C47	Gately et al., (1998), "The Interleukin-12/Interleukin-12 Receptor system: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521.	
	C48	Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206.	
EXAMINER		DATE CONSIDERED 12/19/07	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C49	Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804.	
	C50	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202.	
	C51	Gillies et al., (1990), "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <u>Hum. Antibod. Hybridomas</u> , 1:1:47-54.	
	C52	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Science</u> , 89:1428-1432.	
	C53	Gillies et al., (1993), "Biological Activity and In Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235.	
	C54	Gillies et al., (1998), "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases," <u>J. Immunology</u> , 160:2:6195-6203.	
	C55	Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166.	
	C56	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>Journal of Immunology</u> , 120:6:2027-2032.	
	C57	Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Pharm. Sciences</u> , pp. 597-609.	
	C58	Gren et al., (1983), "A New Type of Leukocytic Interferon," <u>Dokl. Biochem.</u> , 269:91-95.	
	C59	Griffon-Etienne et al., (1999), "Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications," <u>Cancer Research</u> , 59:3776-3782.	
	C60	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73:8:2081-2805.	
	C61	Guyre et al., (1997), "Increased potency of Fc-receptor-targeted antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148.	
	C62	Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Tibtech</u> , 11:42-44.	
	C63	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds FcYRI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotech.</u> , 1:95-105.	
	C64	Harvill et al., (1996), "In vivo properties of an IgG3-IL-2 fusion protein: A general strategy for immune potentiation," <u>Journal of Immunology</u> , 157:7:3165-3170.	
EXAMINER		DATE CONSIDERED 12/19/03	



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann <i>et al.</i> SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C65	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11:6:629-636.	
	C66	He et al., (1998), "Humanization and Pharmacokinetics of Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunol.</u> , 1029-1035.	
	C67	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97:2:331-338.	
	C68	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunol.</u> , 158:4:381-4388.	
	C69	Hellstrom et al., (1986), "Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas," <u>Proc. Natl. Acad. Sci.</u> , 83:18: 7059-7063.	
	C70	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58.	
	C71	Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7:2:159-167.	
	C72	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17:6:1656-1664.	
	C73	Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675.	
	C74	Holden et al., (2001), "Augmentation of Antitumor activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869.	
	C75	Hoogenboom et al., (1991), "Construction and expression of antibody-tumor necrosis factor fusion proteins," <u>Molecular Immunology</u> , 28:9:1027-1037.	
	C76	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096:4:345-354 (Abstract).	
	C77	Hornick et al, (1999), "Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors," <u>Clin. Cancer Res.</u> , 5:51-60.	
	C78	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.	
	C79	Huck et al., (1986), "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human Cy genes," <u>Nucleic Acids Research</u> , Vol. 14:4:1779-1789.	
EXAMINER		DATE CONSIDERED 12/17/03	

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056

APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506

CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647





EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)
C80	Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281.
C81	Ingber et al., (1990), "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <u>Nature</u> , 348:555-557.
C82	Jones et al., (1986), "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <u>Nature</u> , 321:6069-522-525.
C83	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2," <u>Journal of Biological Chemistry</u> , 262:12:5723-5731.
C84	Jung et al., (1986), "Activation of human peripheral blood mononuclear cells by anti-T3: Killing of tumor target cells coated with anti-target-anti-T3 conjugates," <u>Proc. Natl. Acad. Sci.</u> , 83:4479-4483.
C85	Junghans et al., (1996), "The protection receptor of IgG catabolism is the B2-micoglobulin-containing neonatal intestinal transport receptor," <u>Proc. Natl. Acad. Sci.</u> , 93:11:5512-5516.
C86	Kang et al., (1991), "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <u>Proc. Natl. Acad. Sci.</u> , 88:11120-11123.
C87	Kappel et al., (1992), "Regulating gene expression in transgenic animals," <u>Current Opinion in Biotechnology</u> 3:548-553
C88	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFc γ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160:6:1686-1701.
C89	Kendra et al., (1999), "Pharmacokinetics and Stability of the ch 14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunotherapy</u> , 48:219-229.
C90	Kim et al., (1997), "An Ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production," <u>Journal Immunology</u> , 158:9:4137-4144.
C91	Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84.
C92	Kranz et al., (1984), "Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 81:7922-7926.
C93	Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152:6:1233-1246.
C94	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268:31:23311-23317.
EXAMINER	DATE CONSIDERED



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
RM	C95	Lazar et al., (1988), "Transforming Growth Factor α Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8:3:1247-1252.	
	C96	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698.	
	C97	Lieschke, et al., (1997), "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," <u>Nature Biotechnology</u> , 15:1:35-40.	
	C98	Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>Journal of Experimental Medicine</u> , 174:3:561-569.	
	C99	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci.</u> , 82:8648-8652.	
	C100	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398.	
	C101	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92:10:3730-3736.	
	C102	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11:6:495-500.	
	C103	Lode et al., (1998), "Immunocytokines: a promising approach to cancer immunotherapy," <u>Pharmacol. Thera.</u> , 80:3:277-292.	
	C104	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91:5:1706-1715.	
	C105	Lode et al., (1999), "Synergy between an antiangiogenic integrin α_v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases," <u>Proc. Natl. Acad. Sci.</u> , 96:1591-1596.	
	C106	Lode et al., (1999), "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12," <u>Proc. Natl. Acad. Sci.</u> , 96:8591-8596.	
	C107	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29:2:117-120.	
	C108	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84:8:2457-2466.	
	C109	Mark et al., (1992), "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins," <u>Journal of Biological Chemistry</u> , 267:36:26166-26171.	
My	C110	Martinotti et al., (1995), "CD4 T Cells Inhibit in vivo the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146.	
EXAMINER RM		DATE CONSIDERED	2/19/03

NOV 03 2003

SHEET 15 OF 19

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C111	Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158:5:2211-2217.	
	C112	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895.	
	C113	Mosmann et al., (1989), "TH1 and TH2 CELLS: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> , 7:145-173.	
	C114	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.	
	C115	Mullins et al., (1998), "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20:4:473-492.	
	C116	Murphy et al., (1986), "Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related α -melanocyte-stimulating hormone fusion protein," <u>Proc. Natl. Acad. Sci.</u> , 83:8258-8262.	
	C117	Murphy, (1988), "Diphtheria-related peptide hormone gene fusions: A molecular gene approach to chimeric toxin development," <u>Immunotoxins</u> , 123-140.	
	C118	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13:17:6361-6373.	
	C119	Netti et al., (1995), "Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery," <u>Cancer Research</u> , 55:5451-5458.	
	C120	Netti et al., (1999), "Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules," <u>Proc. Nat. Acad. Sci.</u> , 96:3137-3142.	
	C121	Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608.	
	C122	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328.	
	C123	O'Reilly et al., (1996), "Angiostatin induces and sustains dormancy of human primary tumors in mice," <u>Nature Medicine</u> , 2:6:689-692.	
	C124	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285.	
	C125	Pastan et al., (1989), "Pseudomonas Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264:26:15157-15160.	
	C126	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438.	
EXAMINER 		DATE CONSIDERED	



FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: MERCK-2056


APPLICANTS: Hartmann *et al.*

SERIAL NO.: 09/708,506


CONF. NO.: 2626

FILING DATE: November 9, 2000 GROUP: 1647

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
	C127	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target cell antibodies," <u>J. Exp. Medicine</u> , 163:166-178.
	C128	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>Journal of Immunology</u> , 142:10:3662-3667.
	C129	Polizzi et al., (1999), "A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts," <u>Cancer Research</u> , 59:1036-1040.
	C130	Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Nat'l Acad. Sci.</u> , 94:20:10889-10894.
	C131	Reisfeld et al., (1996), "Recombinant antibody fusion proteins for cancer immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 27-53.
	C132	Reisfeld et al., (1997), "Immunocytokines: a new approach to immunotherapy of melanoma," <u>Melanoma Research</u> , 7:2:S99-S106.
	C133	Riethmuller et al., (1994), "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <u>The Lancet</u> , 343:1177-1183.
	C134	Roessler et al., (1994), "Cooperative interactions between the interleukin 2 receptor α and β chains alter the interleukin 2-binding affinity of the receptor subunits," <u>Proc. Natl. Acad. Sci.</u> , 91:3344-3347.
	C135	Roitt et al., (1993), "The Role of Th Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , Third Edition, 8.3-8.4.
	C136	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: current status and future prospects," <u>Immunology Today</u> , 9:2:58-62.
	C137	Rozwarski et al., (1994), "Structural comparisons among the short-chain helical cytokines," <u>Structure</u> , 2:3:159-173.
	C138	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705.
	C139	Sasaki et al., (1998), "Structure, function and tissue forms of the C-terminal globular domain of collagen XVII containing the angiogenesis inhibitor endostatin," <u>The EMBO Journal</u> , 17:15:4249-4256.
	C140	Sauve et al., (1991), "Localization in human interleukin 2 of the binding site of the α chain (p55) of the interleukin 2 receptor," <u>Proc. Natl. Acad. Sci.</u> , 88:4636-4640.
	C141	Schnee et al., (1987), "Construction and expression of a recombinant antibody-targeted plasminogen activator," <u>Proc. Natl. Acad. Sci.</u> , 84:6904-6908.
	C142	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>Journal of Immunology</u> , 148:11:3433-3340.
EXAMINER	DATE CONSIDERED 12/19/03	



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C143	Senter et al., (1988), "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <u>Proc. Natl. Acad. Sci.</u> , 85:13:4842-4846.	
	C144	Shanafelt et al., (2000), "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo," <u>Nature Biotechnology</u> , 18:1197-1202.	
	C145	Sharma et al., (1999), "T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function," <u>Journal of Immunology</u> , 163:5020-5028.	
	C146	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon- λ and is not blocked by human IgG," <u>Journal of Immunology</u> , 137:11:3378-3382.	
	C147	Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503.	
	C148	Shin et al., (1990), "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: Potential applications for cellular targeting," <u>Proc. Natl. Acad. Sci.</u> , 87:5322-5326.	
	C149	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334.	
	C150	Stevenson et al., (1997), "Conjugation of Human Fc γ in Closed-Hinge or Open-Hinge Configuration to Fab' γ and Analogous Ligands," <u>Journal of Immunology</u> , 158:2242-2250.	
	C151	Sulitzeanu et al., (1993), "Immunosuppressive factors in human cancer," <u>Adv. Cancer Research</u> , 60:247-267.	
	C152	Taniguchi et al., (1983), "Structure and expression of a cloned cDNA for human interleukin-2," <u>Nature</u> , 302:305-309.	
	C153	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>Journal of Immunology</u> , 143:8:2595-2601.	
	C154	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>Journal of Experimental Medicine</u> , 178:2:661-667.	
	C155	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925.	
	C156	<u>The Merck Manual of Diagnosis and Therapy</u> , 990-993, 1278-1283 (17 th ed. 1999).	
	C157	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48:5:1119-1123	
	C158	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168	
EXAMINER		DATE CONSIDERED 12/19/03	



FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann et al. SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
<i>R.B.</i>	C159	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027.	
	C160	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470.	
	C161	Varki et al., (1984), "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," <u>Cancer Research</u> , 44:681-687.	
	C162	Verhoeven et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536.	
	C163	Villunger et al., (1997), "Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance," <u>Blood</u> , 90:1:12-20.	
	C164	Watanabe et al., (1997), "Long-term depletion of naive T cells in patients treated for Hodgkin's disease," <u>Blood</u> , 90:9:3662-3672.	
	C165	Williams et al., (1986), "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment," <u>Gene</u> , 43:319-324.	
	C166	Williams et al., (1987), "Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein," <u>Protein Engineering</u> , 1:6:493-498.	
	C167	Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>Journal Immunology</u> , 151: 6602-6607.	
	C168	Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.	
	C169	Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955.	
	C170	Zheng et al., (1995), "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation," <u>Journal of Immunology</u> , 154:5590-5600.	
	C171	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269:3469-3474.	
	C172	International Search Report for International Application No. PCT/EP00/10843, mailed July 20, 2001.	
	C173	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships," <u>J. Biol. Chem.</u> , 268:15983-15993.	
	C174	Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82:1507-1516.	
<i>Ry</i>	C175	Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227:1385-1388	
EXAMINER <i>R M Kelly</i>		DATE CONSIDERED <i>12/19/00</i>	

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: MERCK-2056 APPLICANTS: Hartmann <i>et al.</i> SERIAL NO.: 09/708,506 CONF. NO.: 2626 FILING DATE: November 9, 2000 GROUP: 1647	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
<i>RM</i>	C176	Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13	
	C177	Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527	
	C178	Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131	
	C179	Maddougall, (2002), "Optimizing the Use of Erythropoietic Agents – Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70	
	C180	Nimtz et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56	
<i>RY</i>	C181	Seidenfeld et al., (2001), "Epoetin Treatment of Anemia Associated with Cancer Therapy: a Systematic Review and Meta-analysis of Controlled Clinical Trials," <u>Journal of the National Cancer Institute</u> , 93:1204-1214	
EXAMINER <i>R. M. Tooley</i>		DATE CONSIDERED <i>12/19/03</i>	

2679871-1